

Single-cell multimodal profiling of proteins and chromatin accessibility using PHAGE-ATAC

Evgenij Fiskin^{1,†}, Caleb A Lareau³, Gökcen Eraslan¹, Leif S Ludwig¹, Aviv Regev^{1,2,4,†}

¹Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA

²Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

³Departments of Genetics and Pathology, Stanford University, Stanford, CA, USA

⁴Current address: Genentech, 1 DNA Way, South San Francisco, CA, USA

† To whom correspondence should be addressed: efiskin@broadinstitute.org (EF), aregev@broadinstitute.org (AR)

1 **Abstract**

2 Multi-modal measurements of single cell profiles are a powerful tool for characterizing cell states
3 and regulatory mechanisms. While current methods allow profiling of RNA along with either
4 chromatin or protein levels, connecting chromatin state to protein levels remains a barrier. Here,
5 we developed PHAGE-ATAC, a method that uses engineered camelid single-domain antibody
6 ('nanobody')-displaying phages for simultaneous single-cell measurement of surface proteins,
7 chromatin accessibility profiles, and mtDNA-based clonal tracing through a massively parallel
8 droplet-based assay of single-cell transposase-accessible chromatin with sequencing (ATAC-seq).
9 We demonstrate PHAGE-ATAC for multimodal analysis in primary human immune cells and for
10 sample multiplexing. Finally, we construct a synthetic high-complexity phage library for selection
11 of novel antigen-specific nanobodies that bind cells of particular molecular profiles, opening a new
12 avenue for protein detection, cell characterization and screening with single-cell genomics.

13

14

15 Massively-parallel single-cell profiling has become an invaluable tool for the characterization of
16 cells by their transcriptome or epigenome, deciphering gene regulation mechanisms, and dissecting
17 cellular ecosystems in complex tissues (Klein et al., 2015; Lareau et al., 2019; Macosko et al.,
18 2015; Satpathy et al., 2019). In particular, recent advances have highlighted the power of
19 multimodal single-cell assays (Ma et al., 2020), such as cellular indexing of transcriptomes and
20 epitopes by sequencing (CITE-seq), that profile both transcriptome and proteins by DNA-barcoded
21 antibodies (Mimitou et al., 2019; Peterson et al., 2017; Stoeckius et al., 2017).

22

23 Although the vast combinatorial space of oligonucleotide barcodes theoretically allows parallel
24 quantification of an unrestricted number of epitopes, in practice, however, we are limited by the
25 availability of antigen-specific antibodies. Moreover, each antibody must be separately conjugated
26 with a unique oligonucleotide (oligo)-barcode, which currently does not allow a scalable and
27 pooled construction of barcoded antibody libraries. Finally, technologies for the combined high-
28 throughput measurement of the epigenome and proteome have not been described.

29

30 To overcome these limitations, we developed PHAGE-ATAC (**Figures 1A-1C, Supp. Fig. 1**), a
31 multimodal single-cell approach for phage-based multiplex protein measurements and chromatin
32 accessibility profiling using droplet-based scATAC-seq (10x Genomics scATAC (Satpathy et al.,
33 2019)). PHAGE-ATAC enables sensitive quantification of epigenome and proteins, captures
34 mtDNA that can be used as a native clonal tracer (Lareau et al., 2020; Ludwig et al., 2019),
35 introduces phages as renewable and cost-effective reagents for high-throughput single-cell epitope
36 profiling, and leverages phage libraries for the selection of antigen-specific antibodies

37 (Hoogenboom, 2005; Smith, 1985), altogether providing a novel platform that greatly expands the
38 scope of the single-cell profiling toolbox.

39
40 Protein quantification in PHAGE-ATAC is based on epitope recognition by nanobody (Ingram et
41 al., 2018) (Nb)-displaying phages (**Figure 1A, Supp. Fig. 1**), in contrast to recognition by
42 oligonucleotide-conjugated antibodies in CITE-seq and related methods (Peterson et al., 2017;
43 Stoeckius et al., 2017), or fluorescently labeled antibodies in other techniques (Katzenellenbogen
44 et al., 2020; Paul et al., 2015). The hypervariable complementarity-determining region 3 (CDR3)
45 within each Nb-encoding phagemid acts as a unique genetic barcode (Pollock et al., 2018) that is
46 identified by sequencing in PHAGE-ATAC and serves as a proxy for antigen detection and
47 quantification (**Figure 1A, Supp. Fig. 1A**). To allow phage-based epitope quantification alongside
48 accessible chromatin using droplet-based scATAC-seq, we engineered an M13 phagemid for the
49 in-frame expression of (1) an epitope-binding Nb, (2) a PHAGE-ATAC tag (PAC-tag) containing
50 the Illumina Read 1 sequence (RD1) and (3) the phage coat protein p3 for surface display (**Figures**
51 **1A and 1B**). This enables phage Nb (pNb)-based recognition of cell surface antigens, simultaneous
52 droplet-based indexing of phagemids and ATAC fragments, as well as separate generation of
53 phage-derived tag (PDT) and ATAC sequencing libraries (**Figure 1C, Supp. Fig. 2 and 3**,
54 **Methods**).

55
56 We first confirmed that the PHAGE-ATAC modified phagemid workflow allows successful and
57 specific pNb antigen recognition and pNb-based cell staining during scATAC cell lysis. As a first
58 proof-of-concept, we used HEK293T cells expressing surface-exposed glycosylphosphatidyl-
59 inositol (GPI)-anchored EGFP (EGFP-GPI) that are specifically recognized by an anti-EGFP pNb

60 (Rothbauer et al., 2006) (**Supp. Fig. 4A-4E**). Importantly, introducing the PAC-tag did not impair
61 Nb display and antigen recognition (**Supp. Fig. 4F and 4G**). Moreover, fixation retained pNb-
62 based cell staining after the scATAC lysis step, with a standard scATAC-seq buffer (**Supp. Fig.**
63 **5, Methods**).

64

65 To benchmark PHAGE-ATAC for single cell profiling, we performed a ‘species-mixing’
66 experiment, in which we pooled mouse (NIH3T3), human EGFP⁻ (HEK293T) and human EGFP⁺
67 (HEK293T-EGFP-GPI) cells at a 2:1:1 ratio, followed by anti-EGFP pNb staining, library
68 generation and analysis using a custom computational workflow (**Figure 1D and Supp. Fig. 6**;
69 **Methods**). After filtering, we recovered 1,212 mouse and 1,158 human cell barcodes (**Figure 1E**),
70 with good library complexity, enrichment of fragments in peaks, and enrichment in transcription
71 start sites (**Supp. Fig. 7A-7C**), all comparable to gold-standard published reference data without
72 additional protein detection (Lareau et al., 2020; Satpathy et al., 2019). Analysis of EGFP PDT
73 counts confirmed the presence of EGFP⁺ and EGFP⁻ cells (**Figures 1F and 1G**) that together with
74 mouse cell barcodes were all recovered at expected input ratios (observed 2.09:1:1, expected
75 2:1:1), with no substantial differences in scATAC-seq data quality metrics (**Figure 1H, Supp. Fig.**
76 **7**). EGFP PDT levels by PHAGE-ATAC (**Figures 1F and 1G**) and EGFP fluorescence intensities
77 by standard flow cytometry (**Figure 1I**) were highly concordant (**Figures 1J and 1K**). Taken
78 together, these results established the use of PDTs for accurate and sensitive epitope quantification
79 in single cells concomitantly with scATAC-seq.

80

81 Next, we showed that PHAGE-ATAC can discern cellular states of primary peripheral blood
82 mononuclear cells (PBMCs) comparably to CITE-seq. For PHAGE-ATAC, we targeted well-

83 characterized markers via a panel of three pNbs targeting CD4, CD8 and CD16 using previously
84 reported high-affinity Nb sequences (Roobrouck et al., 2016; Tavernier et al., 2017), as well as
85 anti-EGFP as a negative control (**Methods**). Flow cytometry of pNb-stained PBMCs and side-by-
86 side comparison between pNb and conventional antibody-stained cells confirmed the antigen-
87 specificity of the produced phages (**Supp. Fig. 8**). In addition, we further optimized the PHAGE-
88 ATAC lysis buffer to better preserve phage staining (Lareau et al., 2020) (**Supp. Fig. 9; Methods**).
89 Integrative canonical correlation analysis (Butler et al., 2018), clustering and dimensionality
90 reduction of PHAGE-ATAC data of 7,972 high-quality PBMCs and published CITE-seq data of
91 7,660 PBMCs (Stoeckius et al., 2017) (**Figure 1L, Methods**) identified the same set of expected
92 cell states and markers (**Figure 1L and Supp. Fig. 10A**). The distribution of PDTs and CITE-seq
93 antibody-derived tags (ADTs) across all cell types were highly correlated for each surface marker
94 (**Figures 1M and 1N**, Pearson's $r = 0.69-0.94$). To further validate PDT partitioning independently
95 of CITE-seq, we determined differential gene activity scores from the PHAGE-ATAC data alone
96 by comparing scATAC profiles of T cells based on CD4 and CD8 PDT abundances (**Supp. Fig.**
97 **10B and 10C**). This identified both *CD4* and *CD8* loci as top hits and recovered many known
98 *bona fide* markers of *CD4⁺* and *CD8⁺* T cells (e.g. CD4: *CTLA4*, *CD40LG*, *ANKRD55*; CD8:
99 *PRF1*, *EOMES*, *RUNX3*, **Supp. Fig. 10C**). Finally, EGFP PDTs were only detected at background
100 levels, confirming the high specificity of pNbs (**Supp. Fig. 10D and 10E**). These results illustrate
101 the capacity of PHAGE-ATAC to reliably and specifically detect endogenous cell surface proteins
102 in single cells along with their epigenomic profiles.

103

104 To scale PHAGE-ATAC, we next introduced a cost-effective alternative for sample multiplexing
105 in scATAC-seq using pNbs for Cell Hashing. A number of current methods allow 'overloading'

106 antibody-tagged cells into droplets to increase single-cell processing throughput and mitigate batch
107 effects (Gehring et al., 2020; Lareau et al., 2019; McGinnis et al., 2019; Stoeckius et al., 2018).
108 To demonstrate hashtags for PHAGE-ATAC, we generated four anti-CD8 hashtag pNbs
109 (henceforth referred to as hashtags) by introducing different silent mutations into the anti-CD8
110 CDR3 (**Figure 2A, Methods**), allowing sequencing-based identification of the four hashtags. As
111 expected, the hashtags displayed comparable CD8 recognition within PBMCs (**Supp. Fig. 11A**).
112 To demonstrate phage-based hashing, we stained CD8 T cells from each of four healthy donors
113 with a unique hashtag, pooled them and processed the pool by PHAGE-ATAC, overloading 20,000
114 cells (**Figure 2A**) (vs. ~6000 cells without overloading). These yielded high-quality data for 8,366
115 cell barcodes, to which we assigned donor and singlet/doublet status from hashtag counts
116 (**Methods**), identifying the sample of origin for 6,438 singlets and 703 doublets (observed doublet
117 rate 8.4% compared to 10% expected) (**Figure 2B**). As expected, barcodes assigned to an
118 individual hashtag had higher count distributions for the respective hashtag (**Figure 2C**). Singlet
119 and doublet assignments were concordant with a two-dimensional embedding of hashtag count
120 data (**Figure 2D**), with the expected higher numbers of chromatin fragments and hashtag counts
121 in doublets ($p < 2.2 \times 10^{-16}$; Mann-Whitney test, **Figures 2E and 2F**). The hashtag-based
122 assignments were also highly concordant with assignments based on computationally derived
123 donor genotypes from accessible chromatin profiles (Heaton et al., 2020) (**Methods**), with a singlet
124 classification accuracy of 99.3% and an overall classification accuracy of 92.9% (**Figure 2G**).
125 Interestingly, chromatin accessibility analyses revealed a small set of putative B cells (**Supp. Fig.**
126 **11B and 11C**), consistent with the presence of a minor contaminating population after CD8 T cell
127 enrichment. While B cells were classified as hashtag-negative, genotype and hashtag-based

128 classification were highly consistent across CD8 T cell states (**Figure 2H and Supp. Fig. 11D-**
129 **11F**), confirming hashtag antigen specificity.

130
131 PHAGE-ATAC also enables the concomitant capture of mitochondrial genotypes via
132 mitochondrial DNA-derived Tn5 fragments (Lareau et al., 2020), providing a third data modality
133 that relates protein and accessible chromatin profiles to cell clones. Mitochondrial genotyping
134 using mgatk (Lareau et al., 2020) was broadly concordant with the hashtag assignments, but
135 showed that two donors (PH-B and PH-C) had indistinguishable mitochondrial haplotypes,
136 whereas each of the other two donors had several distinguishing mitochondrial variants (**Supp.**
137 **Fig. 11G**). Collectively, these results established the use of hashtag pNbs for sample multiplexing
138 in scATAC-seq, and its ability to capture mtDNA for clonal analysis.

139
140 The production of novel high-quality antigen-specific antibodies is laborious, expensive and
141 limited by animal immunization, generating a bottleneck for antibody-based protein profiling. In
142 contrast, recombinant antibody technology based on phage display has allowed fast and cost-
143 effective selection of high-affinity binders (Miersch and Sidhu, 2012). To enable rapid generation
144 of novel antigen-specific pNbs for PHAGE-ATAC, we developed PHAGE-ATAC Nanobody
145 Library (PANL), a synthetic high-complexity (4.96×10^9) pNb library (**Supp. Fig. 12**). To
146 demonstrate identification of novel pNbs using PANL, we performed a selection against EGFP-
147 GPI-expressing HEK293T cells, while counter-selecting using parental HEK293T (**Figure 2I**).
148 Over three selection rounds, we monitored the enrichment of pNbs by staining EGFP-GPI⁺ cells,
149 revealing a steady increase of antigen-recognizing pNbs with each additional round (**Figure 2J**).
150 Screening of 94 clones after the final (third) selection demonstrated that at least 95% of clones

151 recognized EGFP-GPI⁺ cells with strong binding (Q2/Q1 >1) (**Figure 2K and Supp. Fig. 13**). As
152 clones varied in their ability to bind EGFP-GPI⁺ cells, we picked 7 clones (5 strong and 2 weak
153 binders) and sequenced their phagemid inserts. Sanger sequencing uncovered the presence of
154 multiple identical clones (A2 and C1, B8 and E3, **Figure 2L**), illustrating selection-driven
155 convergence. Finally, side-by-side comparison of a selected clone (C5) and a reported high-affinity
156 anti-EGFP Nb derived from immunized animals (Rothbauer et al., 2006) indicated similar binding
157 to EGFP-GPI⁺ cells (**Figure 2M**). These results demonstrate the utility of PANL for the rapid
158 selection of pNbs to detect and quantify antigens of interest on cells. They further illustrate
159 PANL's potential for the generation of a new toolbox of barcoded affinity reagents for single cell
160 genomics.

161
162 In conclusion, PHAGE-ATAC uses the power of recombinant phage display technology as the
163 basis for single cell profiling of cell surface proteins, chromatin accessibility and mtDNA. This
164 allows users to leverage the renewable nature, low cost and scalability of pooled phage library
165 preparation as well as the compact size and stability of nanobodies (Ingram et al., 2018). We
166 envisage PHAGE-ATAC as an adaptive tool that may be further combined with unique molecular
167 identifiers for phagemid counting and other engineerable scaffolds used in phage display
168 applications (e.g. scFv, Fab) (Gebauer and Skerra, 2009). In the future, we believe this will
169 significantly enhance our ability for the cost-effective (**Supp. Fig. 14**), multimodal single-cell
170 characterization of the proteome, epigenome and likely additional readouts at an unprecedented
171 depth and specificity.

172

173

174 **Figure legends**

175 **Figure 1. PHAGE-ATAC for massively-parallel simultaneous measurement of protein**
176 **epitopes and chromatin accessibility**

177 **(A)-(C)** PHAGE-ATAC overview. **(A)** Schematic of engineered nanobody-displaying M13
178 phages used for PHAGE-ATAC. Nanobodies are displayed via fusion to p3, the PAC-tag is placed
179 in the linker between nanobody and p3. M13 phagemids contain a pelB leader for periplasmic
180 secretion and incorporation of fusions during phage assembly. **(B)** PAC-tag RD1 sequence (pink)
181 allows capture by 10x ATAC gel bead oligos (**Supp. Fig. 2A**), without interrupting translation
182 (right). **(C)** PHAGE-ATAC workflow. After phage nanobody staining, fixation, lysis and
183 fragmentation in bulk (leftmost), single cells and 10x ATAC gel beads are encapsulated into
184 droplets using 10x microfluidics, followed by linear amplification with simultaneous droplet
185 barcoding of chromatin fragments and phagemids via hybridization of 10x barcoding primers to
186 RD1 sequences (second from left). Separate PDT and ATAC sequencing libraries are prepared
187 (second from right and **Supp. Fig. 3**). Right: Representative BioAnalyzer traces. BC, bead
188 barcode. **(D)-(K)** Single-cell ATAC and EGFP specificity in a species-mixing experiment. **(D)**
189 Experimental scheme. **(E)** Number of human (x axis) and mouse (y axis) ATAC fragments
190 associated with each bead barcode (dots), colored by assignment as human EGFP+ (light blue),
191 human EGFP- (dark blue), mouse (red), doublet (purple, >10% human and mouse fragments). **(F)**
192 EGFP PDT counts (y axis, \log_{10} scale) and number of ATAC fragments (x axis, \log_{10} scale) for
193 each bead barcode (dots) colored as in E (color legend). **(G),(H)** Distributions of EGFP PDTs (G,
194 y axis, \log_{10} scale) and ATAC fragments (H, y axis, \log_{10} scale) in each of the three populations
195 (x axis) (Mann-Whitney one-tailed, *** $p < 10^{-4}$, NS=not significant). Line: median. **(I)-(K)** PDT
196 quantification is consistent with flow cytometry. EGFP fluorescence (I, y axis) and distribution (J,

197 x axis) and distribution of EGFP PDT (K, x axis) in EGFP+ (light blue) and EGFP- (dark blue)
198 human cells. (L)-(N) PHAGE-ATAC and CITE-seq compare well in human PBMCs. (L),(M)
199 Two-dimensional joint embedding of scRNA-seq profiles from PBMCs from published CITE-seq
200 (Stoeckius et al., 2017) and of scATAC-seq profiles from PBMCs generated by PHAGE-ATAC ,
201 colored by annotated cell types (L) or by the level of protein marker ADTs (M, top) or PDTs (M,
202 bottom). (N) Agreement between protein level estimates from CITE-seq and PHAGE-ATAC.
203 ADT (y axis, centered log ratio (CLR)) and PDT (x axis, CLR) for each marker gene across cell
204 types (dots, colored as in L), Pearson's r is shown.

205

206 **Figure 2. PHAGE-ATAC compatible phage nanobodies enable sample multiplexing and can**
207 **be selected using phage display**

208 **(A)** Generation of phage hashtags by silent mutations. Shown is a schematic for four anti-CD8
209 phage hashtags and a subsequent hashing experiment using CD8 T cells from four human donors.
210 **(B)-(H)** Effective demultiplexing of phage hashtags. **(B)** PDT counts (color bar, CLR) for each
211 hashtag (rows) across cells (columns) sorted by their HTODemux classification (Phage hash ID).
212 **(C)** PDT count distributions for each hashtag (colored histograms) across the four Phage hash IDs
213 (Wilcoxon two-tailed, ***p < 10⁻⁴). **(D)** Two-dimensional embedding of cell barcodes by PDT
214 count data, colored by PDT count for the marked hashtag (4 left panels) or by singlet/doublet
215 classification (right). **(E),(F)** Distribution of the number of ATAC fragments per barcode (E, y
216 axis) or PDT counts (F, y axis) in cell barcodes in each category (x axis) (Mann-Whitney two-
217 tailed, ***p < 10⁻⁴, NS=not significant). Line: median. **(G)** Number and percent (color) of barcodes
218 shared between each genotype-based (Genotype ID, rows) and Phage hashtag ID-based (columns)
219 assignments. Top: overall accuracy. **(H)** Proportion of cells of each type (y axis) within each
220 assigned barcode category (x axis) based on either genotype (left) or and hashtags (right), and in
221 the negative fraction (far right). **(I)-(M)**, Selection of PHAGE-ATAC nanobodies by phage
222 display. **(I)** Schematic of phage display selection using PANL (**Methods**). PANL is panned against
223 EGFP-expressing cells (HEK293T-EGFP-GPI) with preceding counter-selection against antigen-
224 devoid parental cells (HEK293T). Bound phages are eluted, used to infect bacterial hosts and
225 output libraries are generated. After multiple selection rounds, antigen-recognizing phage
226 nanobody clones are picked, phagemids are isolated and nanobody inserts are sequenced. **(J)** Flow
227 cytometry analysis of selection progress. Flow cytometry plots of EGFP fluorescence (y axis) and
228 phage binding (x axis, AlexaFluor647 area) to EGFP-GPI-expressing HEK293T cells (EGFP^{hi} and

229 EGFP^{lo}) in, from left, the input library and after each of three consecutive selection cycles (see
230 also **Supp. Fig. 4C and Methods**). **(K)** Flow cytometry screen of 94 phage nanobody clones
231 derived from selection round 3. Ratio of Q2 to Q1 signal (as defined in **Figure 1J**) when staining
232 EGFP-GPI-expressing HEK293T (EGFP^{hi} and EGFP^{lo}) cells with individual phage nanobodies
233 after the 3rd round of selection. Dashed line: threshold of Q2/Q1=1 used for calling positive clones.
234 **(L)** CDR sequences and CDR3 length of selected clones obtained by Sanger sequencing. * non-
235 randomized constant positions in PANL library (see also **Supp. Fig. 12A**). **(M)** Flow cytometry
236 plots of EGFP fluorescence (y axis) and phage binding (x axis, AlexaFluor647 area) to EGFP-
237 GPI-expressing HEK293T cells (EGFP^{hi} and EGFP^{lo}) using an immunization-based (Rothbauer et
238 al., 2006) anti-EGFP Nb-displaying phage (middle), clone C5 from our screen (right) and an anti-
239 mCherry phage negative control (left).

240

241

242 **Supplementary Figure legends**

243 **Supplementary Figure 1: Barcoding strategies for epitope quantification by PHAGE-ATAC**

244 **vs. CITE-seq**

245 **(A)** Nanobody-displaying phages for PHAGE-ATAC. The phagemid contained within a particular

246 phage particle encodes the protein displayed on that same phage, and PHAGE-ATAC leverages

247 the hypervariable nanobody CDR3 sequences as unique genetic barcode identifiers for each phage.

248 **(B)** Oligonucleotide-conjugated antibodies for CITE-seq. Each antibody is separately conjugated

249 with a unique DNA-barcode.

250

251

252 **Supplementary Figure 2. Phage barcode amplification using 10x Genomics scATAC-seq**

253 **primers enabled by a modified Illumina Read 1 (RD1) sequence**

254 **(A)** Schematic of gel bead oligos showing Illumina P5 sequence (P5), random bead barcode (BC)
255 and the first 14bp of RD1 used for hybridization with RD1-containing chromatin fragments and
256 engineered PHAGE-ATAC phagemids. **(B)** Nanobody-encoding phagemid constructs for RD1-
257 mediated CDR3 barcode capture by 10x Genomics primers. The top strand is the coding strand.
258 Orientation (arrows and shaded boxes), nucleotide sequence and translation product of RD1-
259 containing constructs are shown. To avoid generating a stop codon by introduction of RD1 into
260 the nanobody-p3 reading frame additional codons are introduced to maintain the reading frame
261 across RD1, thus establishing the PAC tag. **(C)** Agarose gel after two-step PCR consisting of linear
262 amplification using the 10x ATAC primer followed by exponential PCR using P5 and Illumina
263 Read 2 (RD2)-containing nanobody-specific primers. PDTs were only obtained for PAC-tagged
264 phagemids with RD1 located on the non-coding strand (3'-5' orientation relative to nanobody).
265 Abbreviations as in A. Control PCR was performed using two primers hybridizing within the
266 nanobody sequence (**Methods**).

267

268

269 **Supplementary Figure 3. Workflow for separate preparation of scATAC and PDT libraries**

270 **after droplet-based indexing**

271 Schematic of post barcoding steps for the generation of ATAC and PDT sequencing libraries

272 **(Methods).** After breaking emulsions, barcoded linear amplification products are purified and

273 samples are split. ATAC fragment libraries are immediately processed for sample index PCR. PDT

274 libraries are first amplified in a PDT-specific PCR using a CDR3 flanking constant nanobody

275 sequence as PCR handle. PDT amplification allows RD2 adapter introduction required for final

276 sample indexing. P5 and P7, Illumina P5 and P7 sequences. CBC, random 10x bead cell barcode.

277 i7, sample index.

278

279

280 **Supplementary Figure 4. Detection of membrane-localized EGFP via anti-EGFP nanobody-**
281 **displaying phages**

282 **(A),(B)** Membrane expressed EGFP. **(A)** Microscopy images of HEK293T cells expressing
283 indicated constructs, showing differential localization of untagged cytosolic EGFP (pCAG-EGFP,
284 middle) and GPI-anchored membrane-localized EGFP (pCAG-EGFP-GPI, right, **Methods**). **(B)**
285 Schematic of surface-exposed GPI-anchored EGFP. **(C)** Schematic for detection of phage
286 recognition via flow cytometry. Phage-stained cells are incubated with mouse anti-M13 coat
287 protein antibodies followed by detection by Alexa Fluor 647-conjugated anti-mouse secondary
288 antibodies. Phage binding is thus reflected by Alexa Fluor 647 signal. **(D)** Flow cytometry analysis
289 of anti-EGFP phage nanobody binding to EGFP-expressing HEK293T cells. EGFP fluorescence
290 (y axis) and phage binding (x axis, Alexa Fluor 647) in each of the HEK293T cell populations as
291 in **A**, either unstained (left) or stained with an anti-EGFP phage (right). EGFP-expressing cells
292 were always characterized by the presence of both EGFP^{hi} and EGFP^{lo} populations. **(E)** Specificity
293 of detection. As in **D** but using the indicated staining controls for specific staining of membrane-
294 EGFP-expressing cells. **(F),(G)** PAC-tag does not impact nanobody display and antigen
295 interaction. EGFP fluorescence (F, y axis) and phage binding (F, x axis, Alexa Fluor 647) and
296 distribution of level of phage binding (G) for phage-stained EGFP-GPI expressing cells using
297 indicated phage nanobodies (for RD1 sequences see **Supp. Fig. 2B**).

298

299

300 **Supplementary Figure 5. Optimization of fixation and lysis conditions for PHAGE-ATAC**

301 **species-mixing experiment**

302 EGFP fluorescence (A, y axis) and phage binding (A, x axis, Alexa Fluor 647) and distribution of

303 level of phage binding (B) for EGFP-GPI expressing cells stained with PAC-tagged anti-EGFP-

304 Nb displaying phages after fixation and permeabilization using indicated conditions.

305

306

307 **Supplementary Figure 6. Computational workflow for PHAGE-ATAC data analysis**

308 Paired-end sequencing output is demultiplexed using sample index information (left) to recover
309 ATAC and PDT fastqs. ATAC fastqs are processed using CellRanger-ATAC count for fragment
310 alignment, assignment of cell barcodes and generation of peak-cell barcode matrices. CDR3
311 barcode sequences are used to search PDT_R3 fastqs and identify CDR3-containing sequencing
312 clusters. Matching of cluster identifiers is used to derive corresponding cell barcodes from
313 PDT_R2 fastqs. Recovered PDT cell barcode lists are filtered using cell barcodes called by
314 CellRanger. Cell barcode occurrences are counted to generate PDT-cell barcode count matrices
315 **(Methods)**.

316

317

318 **Supplementary Data Figure 7. PHAGE-ATAC quality metrics for human-mouse species-
319 mixing experiment**

320 **(A)** Fraction (y axis) and number (x axis, \log_{10} scale) of unique chromatin fragments overlapping
321 peaks for each barcode (dot) colored by populations (color legend). **(B),(C)** Distribution of fraction
322 of unique ATAC fragments overlapping peaks (B, y axis) or TSS (C, y axis) in each of the three
323 cell populations (x axis) (Mann-Whitney two-tailed, *** $p < 10^{-4}$, NS=not significant). Line:
324 median.

325

326

327 **Supplementary Figure 8. Validation of PAC-tagged anti-CD4, anti-CD8 and anti-CD16**

328 **nanobody-displaying phages**

329 **(A)** Flow cytometry gating strategy for analyzed phage-stained PBMCs. **(B)** Flow cytometry-based
330 binding assessment of indicated surface marker-recognizing phage nanobodies to gated
331 lymphocyte and monocyte populations, anti-EGFP pNb was used as negative control. **(C)**
332 Comparison of PBMCs stained with a well-characterized anti-CD4 antibody or generated anti-
333 CD4 phage nanobody. Phage binding is reflected by Alexa Fluor 647 fluorescent signal intensity.

334

335

336 **Supplementary Figure 9. Optimization of fixation and lysis conditions for PHAGE-ATAC**
337 **using PBMCs**

338 **(A)** Binding of generated anti-CD4 phage nanobodies to PBMCs under indicated conditions. Two
339 different formaldehyde concentrations as well as various depicted lysis buffers were used. Phage
340 binding is reflected by Alexa Fluor 647 fluorescent signal intensity. **(B)** Histogram of data in **(A)**.

341

342

343 **Supplementary Figure 10. Multimodal single-cell analysis of human PBMCs using PHAGE-**
344 **ATAC**

345 **(A)** Two-dimensional joint embedding of scRNA-seq profiles from PBMCs from published CITE-
346 seq (Stoeckius et al., 2017) and of scATAC-seq profiles from PBMCs generated by PHAGE-
347 ATAC, colored by the measured RNA level from CITE-Seq (top panels) or by gene activity scores
348 from PHAGE-ATAC (bottom panels) (**Methods**). **(B),(C)** PHAGE-ATAC gating by phage
349 staining highlights cell type specific loci. **(B)** PDT count-based classification of CD4⁺ and CD8⁺
350 T cells. PDT counts (CLR transformed) of CD8 (y axis) and CD4 (x axis) in each cell (dots). Red
351 boxes: gates for CD4+ and CD8+ cells. **(C)** Average fold change (x axis, log₂) and associated
352 significance (y axis, -log₁₀(P-value) for each gene activity comparing between PDT-classified CD4
353 and CD8 T cells shown in B. Known *bona fide* markers of either CD4 or CD8 T cells are marked.
354 **(D)** Negative control. Embedding of PHAGE-ATAC data as in A, colored by anti-EGFP pNb PDT.
355 **(E)** Distribution of phage counts (y axis, log₁₀) for each cell barcode for each assayed nanobody
356 (x axis).

357

358

359 **Supplementary Figure 11. Sample multiplexing using hashtag phages**

360 **(A)** Validation of phage hashtag binding. Flow cytometry of anti-CD8 hashtag phages bound
361 (Alexa Fluor 647 fluorescent signal, x axis) to lymphocytes gated via flow cytometry of phage-
362 stained PBMCs (as shown in **Supp. Fig. 8A**). **(B)** Cell type identification. Two-dimensional
363 embedding of hashed CD8 T cells analyzed by PHAGE-ATAC, colored by cell type annotation.
364 **(C)** Pseudobulk chromatin accessibility track plots for *CD8*, *CD3* and *MS4A1* (*CD20*) loci across
365 identified cell types. **(D)** Embedding as in B with cells colored by CD8 hashtag PDTs. **(E),(F)**
366 Distribution of maximal CD8 PDT density (E, y axis) or unique chromatin fragments (F, y axis)
367 for each cell barcode in CD8⁻ (B cell 1 and B cell 2) and CD8⁺ (non-B cell) cells (x axis) (Mann-
368 Whitney two-tailed, ***p < 10⁻⁴). **(G)** Concordance between hashtag-based classification of
369 barcodes and identified mtDNA SNPs. Heteroplasmy (allele frequency percentage; color bar) of
370 different mtDNA variants (rows) in each cell (column), labeled by hashtag assignment (vertical
371 top color bar).

372

373

374 **Supplementary Figure 12. Establishment of PANL, a fully synthetic high-complexity PAC-**
375 **tagged phage nanobody library**

376 **(A)** Schematic of PANL library design and library phagemid. CDR3 sequence diversification and
377 nanobody framework (grey) in PANL are based on a previously reported nanobody randomization
378 strategy (McMahon et al., 2018). White box: expected frequency of amino acids at each
379 hypervariable position (denoted by X), adjusted by using a custom randomized primer mix for
380 library generation (**Methods**). CDR3 loops contained either 7, 11 or 15 hypervariable positions,
381 resulting in total CDR3 lengths of 10 (short), 14 (medium) or 18 (long) amino acids. Partially
382 randomized positions are depicted as columns, constant positions contain a single amino acid. A
383 deposited structure of anti-EGFP Nb (PDB: 3ogo (Kubala et al., 2010)) with colored CDR3 loops
384 is shown. PANL phagemid is analogous to the one shown in **Figure 1A**. **(B)** Expected (grey) and
385 observed (red) frequencies (x axis) of amino acids at hypervariable positions (y axis) (**Methods**).
386 **(C)** Amplification products of phagemid insert-spanning PCR reactions using depicted primers for
387 25 randomly picked PANL clones. Product sizes due to presence of long, medium or short CDR3
388 are shown. **(D)** CDR3 sequences of selected clones from C obtained by Sanger sequencing, CDR3
389 length is indicated, * non-randomized constant positions in the PANL library.

390

391

392 **Supplementary Figure 13. Flow cytometry-based screen of nanobody-displaying phage**

393 **clones from selection round 3**

394 Flow cytometry analysis of round 3 phage nanobody clones for binding to EGFP-GPI expressing
395 cells (EGFP^{hi} and EGFP^{lo} populations can be observed) with either strong (A) or weaker (B)
396 binders. Phage nanobodies against mCherry were used as negative control. Phage binding is
397 reflected by Alexa Fluor 647 signal.

398

399

400 **Supplementary Figure 14. Estimates of cost per reaction for phage nanobodies**

401 Comparison of cost estimates per reaction step and overall for a phage nanobody produced

402 recombinantly.

403

404

405 **Methods**

406 **Oligonucleotides**

407 Oligonucleotide sequences are listed in **Supplementary Table 1**. Oligonucleotides were ordered
408 from Integrated DNA Technologies (IDT) unless indicated otherwise.

409

410 **Cloning of phagemids for display of PAC-tagged nanobody-p3 fusions for PHAGE-ATAC**

411 Based on the 10x scATAC bead oligo design (**Supp. Fig. 2A**), we hypothesized that introduction
412 of an RD1 flanking the Nb CDR3 barcode would enable barcode capture alongside accessible
413 chromatin fragments during droplet-based indexing. To avoid premature termination of nanobody-
414 p3 fusion translation due to the introduction of RD1, we modified the RD1-spanning reading
415 frame, which resulted in the expression of a 12-amino acid PHAGE-ATAC tag (PAC-tag). To
416 generate a phagemid for C-terminal fusion of both PAC-tag and p3, 20ng pDXinit (Addgene ID:
417 110101) were subjected to site-directed mutagenesis with primers EF77 and EF78 using PfuUltraII
418 (Agilent) in 50μl reactions. PCR conditions were 95°C 3min; 19 cycles 95°C 30sec, 60°C 1min,
419 68° 12min; final extension 72°C 14min. Template DNA was digested for 1.5h at 37°C by addition
420 of 1.5μl DpnI (Fastdigest, Thermo Scientific). PCR reactions were then purified using GeneJet
421 Gel Extraction Kit (Thermo Scientific) and eluted in 45μl water. 20μl eluate were transformed into
422 chemically-competent *E. coli* (NEB Stable Competent) and plated on LB-Ampicillin, yielding
423 pDXinit-PAC. For cloning of nanobody-PAC-p3 fusion-encoding phagemids, nanobody
424 sequences (**Supplementary Table 3**) were ordered as gBlocks from IDT. 25ng nanobody gBlocks
425 were first amplified by PCR to introduce SapI restriction sites. Primers EF87 and EF88 were used
426 for CD4 Nb, primers EF87 and EF89 for CD16 Nb and primers EF104 and EF105 for CD8 Nb.
427 50μl PCR reactions using Q5 (NEB) were cycled 98°C 1min; 35 cycles 98°C 15sec, 60°C 30sec,

428 72° 30sec; final extension 72°C 3min. PCR reactions were loaded on a 1% agarose gel, expected
429 bands were cut and PCR products were extracted using GeneJet Gel Extraction Kit (Thermo
430 Scientific) and eluted in 40µl water. Cloning was performed using the FX system as described
431 previously (Geertsma and Dutzler, 2011). Briefly, each eluted insert was mixed with 50ng
432 pDXinit-PAC in a molar ratio of 1:5 (vector:insert) in 10µl reactions and digested with 0.5µl SapI
433 (NEB) for 1h at 37°C. Reactions were incubated for 20min at 65°C to heat-inactivate SapI, cooled
434 down to room temperature and constructs were ligated by addition of 1.1µl 10x T4 ligase buffer
435 (NEB) and 0.25µl T4 ligase (NEB) and incubation for 1h at 25°C. Ligation was stopped by heat-
436 inactivation for 20min at 65°C followed by cooling to room temperature. 2µl ligation reactions
437 were transformed into chemically-competent *E. coli* (NEB Stable Competent) and plated on 5%
438 sucrose-containing LB-Ampicillin, yielding pDXinit-CD4Nb-PAC, pDXinit-CD8Nb-PAC and
439 pDXinit-CD16Nb-PAC. For cloning of CD8 hashtag phagemids, 20ng pDXinit-CD8Nb-PAC
440 were used as template for site-directed mutagenesis (as described earlier in this section) using
441 primers EF156 and EF157 to generate pDXinit-CD8Nb(PH-A)-PAC, primers EF158 and EF159
442 for pDXinit-CD8Nb(PH-B)-PAC, primers EF164 and EF165 for pDXinit-CD8Nb(PH-C)-PAC
443 and primers EF166 and EF167 for pDXinit-CD8Nb(PH-D)-PAC. For cloning of EGFP Nb-
444 displaying phagemids, the EGFP Nb sequence from pOPINE GFP nanobody (Addgene ID: 49172)
445 was amplified in 50µl PCR reactions with Q5 (NEB) using 25ng plasmid template and EF05 and
446 EF06 primers. The EGFP nanobody insert was cloned into pDXinit using FX cloning (described
447 earlier), yielding pDXinit-EGFPNb. EGFP Nb-displaying phagemids containing RD1 in different
448 orientations were cloned by using pDXinit-EGFPNb and performing site-directed mutagenesis
449 (described earlier) with EF73 and EF74 to obtain pDXinit-EGFPNb-PAC or using EF75 and EF76
450 yielding pDXinit-EGFPNb-RD1(5-3). For introduction of a PCR handle required for PDT library

451 amplification, pDXinit-EGFPNb-PAC was subjected to site-directed mutagenesis (as described
452 earlier in this section) using primers EF78 and EF79, yielding pDXinit-EGFPNb(handle)-PAC.
453 For cloning of mCherry Nb-displaying phagemids, the mCherry Nb sequence from pGex6P1
454 mCherry nanobody (Addgene ID: 70696) was amplified in 50 μ l PCR reactions with Q5 (NEB)
455 using 25ng plasmid template and EF07 and EF08 primers. The mCherry nanobody insert was
456 cloned into pDXinit using FX cloning (as described earlier in this section), yielding pDXinit-
457 mCherryNb. All constructs are listed in Supplementary Table 2.

458

459 **Analysis of RD1-mediated phagemid amplification using RD1-containing primers**

460 5ng of either pDXinit-EGFPNb, pDXinit-EGFPNb-PAC or pDXinit-EGFPNb-RD1(5-3) were
461 subjected to linear PCR (10 μ l reaction volume) using primer EF170 and 5 μ l 2x KAPA HiFi
462 HotStart ReadyMix (Roche) and cycling conditions 98°C 2min; 12cycles 98°C 10sec, 59°C 30sec,
463 72°C 1min; final extension 72°C 5°min. After completion, 0.625 μ l of each primer EF147 and
464 EF57, 1.25 μ l water and 12.5 μ l 2x KAPA were added. Nb-specific PCR was performed using 98°C
465 3min; 30cycles 98°C 15sec, 65°C 20sec, 72°C 1min; final extension 72°C 5min. PCR using
466 primers EF57 and EF58 and indicated plasmid templates was used as amplification control.

467

468 **Phage production**

469 Phagemid-containing SS320 (Lucigen) cultures were incubated overnight in 2YT medium
470 containing 2% glucose, 50 μ g/ml Ampicillin and 10 μ g/ml Tetracycline (2YT/2%/A/T) at 37°C,
471 240rpm. Cultures were diluted 1:50 in 2YT/2%/A/T and grown for 2-3h at 37°C, 240rpm until
472 OD600 = 0.4-0.5. 5ml bacteria were then infected with 200 μ l M13K07 helper phage (NEB) and
473 incubated for 60min at 37°C. Bacteria were collected by centrifugation and resuspended in 50ml

474 2YT containing 50 μ g/ml Ampicillin and 25 μ g/ml Kanamycin (2YT/A/K). Phages were produced
475 overnight by incubation at 37°C, 240rpm. Cultures were centrifuged and phages were precipitated
476 from supernatants by addition of 1/4th volume 20% PEG-6000/2.5M NaCl solution and incubation
477 on ice for 75min. Phages were collected by centrifugation (17min, 12500g, 4°C). Phage pellets
478 were resuspended in 1.2ml PBS, suspensions were cleared (5min, 12500g, 25°C) and supernatants
479 containing phages were stored.

480

481 **Cell culture**

482 NIH3T3 and HEK293T cells (ATCC) were maintained in DMEM containing 10% FBS, 2 mM L-
483 glutamine and 100 U/ml penicillin/streptomycin (Thermo Scientific) and cultured at 37°C and 5%
484 CO₂. For sub-culturing, medium was aspirated, cells were washed with PBS and detached with
485 Trypsin-EDTA 0.25% (Thermo Scientific). Detachment reactions were stopped with culture
486 medium and cells were seeded at desired densities. Cell stocks were prepared by resuspending cell
487 aliquots in FBS with 10% DMSO and freezing them slowly at -80°C. Frozen aliquots were then
488 moved to liquid nitrogen for long-term storage. All cell lines were regularly tested for mycoplasma
489 contamination.

490

491 **Plasmid transfection of HEK293T cells**

492 One day before transfection, 2x10⁶ HEK293T cells were seeded in 10cm dishes (Corning) in
493 complete culture medium (as described in section ‘Cell culture’). Transfection was performed
494 using GeneJuice reagent (Fisher Scientific). 600 μ l Opti-MEM and 12 μ l GeneJuice were mixed in
495 1.5ml tubes, vortexed shortly and spun down. 4 μ g of plasmid DNA (either pCAG (Addgene ID:
496 11160), pCAC-EGFP (Addgene ID: 89684) or pCAC-EGFP (Addgene ID: 32601)) were added,

497 tubes were vortexed shortly and spun down. Transfection mix was added dropwise to HEK293T
498 cells. Cells were grown for 24h at 37°C and 5% CO₂ to allow transgene expression. Successful
499 transfection was assessed by fluorescence microscopy on an EVOS M5000.

500

501 **Flow cytometry for detection of phage binding**

502 Harvested cell lines or thawed PBMCs (see PHAGE-ATAC workflow for harvest and thawing
503 protocol) were resuspended in FC buffer (above) and incubated with respective phage nanobodies
504 for 20min on a rotator at 4°C. Cells were centrifuged and washed with cold FC buffer twice to
505 remove unbound phages (all centrifugation steps were 350g, 4min, 4°C). For optimization of
506 fixation and lysis conditions, cells were fixed using indicated formaldehyde concentrations
507 (Thermo Scientific) and permeabilized with depicted lysis buffers. Cells were resuspended in FC
508 buffer and anti-M13 antibody (Sino Biological, 11973-MM05T-50) was added at 1:500 dilution.
509 After 10min on ice, cells were washed twice in FC buffer and anti-mouse Fc Alexa Fluor 647-
510 conjugated secondary antibody (Thermo Scientific, A-21236) was added at 1:500 dilution. Cells
511 were incubated for 10min on ice, washed twice in FC buffer and resuspended in Sytox Blue
512 (Thermo Scientific) containing FC buffer for live/dead discrimination according to manufacturer's
513 instructions. In indicated cases, cells were stained with anti-CD4-FITC (clone OKT4, BioLegend)
514 at 1:500 dilution, hereby no anti-M13 and anti-mouse Fc antibodies were used. Stained cells were
515 analyzed using a CytoFLEX LX Flow Cytometer (Beckman Coulter) at the Broad Institute Flow
516 Cytometry Facility. Flow cytometry data were analyzed using FlowJo software v.10.6.1.

517

518 **PHAGE-ATAC workflow**

519 For cell line “species mixing” experiment, culture medium was aspirated, cell lines were washed
520 with PBS, harvested using Trypsin-EDTA 0.25% (Thermo Scientific), resuspended in DMEM
521 containing 10% FBS, centrifuged, washed with PBS and resuspended in FC buffer. For PBMC
522 and CD8 T cell experiments, cryopreserved PBMCs or CD8 T cells (AllCells) were thawed,
523 washed in PBS and resuspended in cold Flow cytometry buffer (FC buffer; PBS containing 2%
524 FBS). All centrifugation steps were carried out at 350g, 4min, 4°C unless stated otherwise.

525

526 Cells were incubated with phages on a rotating wheel for 20min at 4°C. After three washes in FC
527 buffer, cells were fixed in PBS containing 1% formaldehyde (Thermo Scientific) for 10min at
528 room temperature. Fixation was quenched by addition of 2.5M glycine to a final concentration of
529 0.125M. Cells were washed twice in FC buffer and permeabilized using lysis buffer (10mM Tris-
530 HCl pH 7.5, 10mM NaCl, 3mM MgCl₂, 0.1% NP-40, 1% BSA) for 3min on ice. This buffer was
531 used, as we found that standard 10x Genomics scATAC lysis buffer results in loss of pNb cell
532 staining (**Supp. Fig. 9**). After lysis, cells were washed by addition of 1ml cold wash buffer (lysis
533 buffer without NP-40), inverted and centrifuged (5min, 500g, 4°C). Supernatant was aspirated and
534 the cell pellet was resuspended in 1x Nuclei Dilution Buffer (10x Genomics). Cell aliquots were
535 mixed with Trypan Blue and counting was performed using a Countess II FL Automated Cell
536 Counter. Processing of cells for tagmentation, loading of 10x Genomics chips and droplet
537 encapsulation via the 10x Genomics Chromium controller microfluidics instrument was performed
538 according to Chromium Single Cell ATAC Solution protocol.

539

540 For species-mixing, a single 10x channel was ‘super-loaded’ with 20,000 cells. Linear
541 amplification and droplet-based indexing were performed as described in the 10x ATAC protocol

542 on a C1000 Touch Thermal cycler with 96-Deep Well Reaction Module (BioRad). After linear
543 PCR, droplet emulsions were broken, barcoded products were purified using MyONE silane bead
544 cleanup and eluted in 40 μ l elution buffer I (Chromium Single Cell ATAC Solution protocol). At
545 this point eluates were split for PDT and ATAC library preparation. Whereas 5 μ l eluate were used
546 for PDT library preparation as described below, the remaining 35 μ l eluate were used for scATAC
547 library generation (according to Chromium Single Cell ATAC Solution protocol). Splitting
548 samples at this point is not expected to result in a loss of library complexity as PDTs and ATAC
549 fragments already underwent amplification via linear PCR.

550

551 The aliquot for PDT library preparation was used for PDT-specific PCR in a 100 μ l reaction using
552 2x KAPA polymerase and primers EF147 and EF91, cycling conditions were: 95°C 3min, 20cycles
553 95°C 20sec, 60°C 30sec, 72° 20sec; final extension 72°C 5min. Amplified PDT products were
554 purified by addition of 65 μ l SPRIselect beads (Beckman Coulter), 160 μ l supernatants were saved
555 and incubated with 192 μ l SPRIselect. Beads were washed twice with 800 μ l 80% ethanol and the
556 PDT library was eluted in 40 μ l buffer EB (Qiagen).

557

558 Concentration of PDT libraries was determined and 15ng were used for 100 μ l indexing PCR
559 reactions using 50 μ l Amp-Mix (10x Genomics), 7.5 μ l SI-PCR Primer B (10x Genomics) and 2.5 μ l
560 i7 sample index-containing primers (10x Genomics), cycling conditions were: 98°C 45sec; 6cycles
561 98°C 20sec, 67°C 30sec, 72° 20sec; final extension 72°C 1min. Indexed PDT libraries were
562 purified by addition of 120 μ l SPRIselect and eluted in 40 μ l buffer EB. The concentration of final
563 libraries was determined using a Qubit dsDNA HS Assay kit (Invitrogen) and size distribution was
564 examined by running a High Sensitivity DNA chip on a Bioanalyzer 2100 system (Agilent).

565

566 PDT and ATAC libraries were pooled and paired-end sequenced (2 x 34 cycles) using Nextseq
567 High Output Cartridge kits on a Nextseq 550 machine (Illumina). Raw sequencing data were
568 demultiplexed with CellRanger-ATAC mkfastq. ATAC fastqs were used for alignment to the
569 GRCh38 or mm10 reference genomes using CellRanger-ATAC count version 1.0.

570

571 **Computational workflow for generation of PDT count matrices**

572 PDT fastqs were obtained by running CellRanger-ATAC mkfastq on raw sequencing data and
573 custom UNIX code was used to derive PDT-cell barcode count tables. For each lane, using ‘grep
574 -B1’ function, PDT_R3 fastqs were searched for each CDR3 barcode sequence (**Supplementary**
575 **Table 4**) and corresponding sequencing cluster information was derived. Cluster information was
576 used to derive corresponding cell barcodes from PDT_R2 fastqs by using ‘fgrep -A1 -f’. Files
577 containing identified cell barcodes from all four lanes were concatenated, the reverse complement
578 of cell barcode sequences was generated using ‘tr ACGTacgt TGCAtgca’ and barcodes were
579 filtered via ‘fgrep -f’ using the cell barcodes called by CellRanger-ATAC count. Unique cell
580 barcode occurrences were counted.

581

582 **Analysis of species mixing PHAGE-ATAC experiment**

583 PHAGE-ATAC sequencing data from the species-mixing experiment was demultiplexed using
584 CellRanger-ATAC mkfastq and generated ATAC fastqs were processed with CellRanger-ATAC
585 count to filter reads, trim adapters, align reads to both GRCh38 and mm10 reference genomes,
586 count barcodes, identify transposase cut sites, detect accessible chromatin peaks and to identify
587 cutoffs for cell barcode calling. The “force-cells” parameter was not set. Barcodes were classified

588 as human or mouse if >90% of barcode-associated fragments aligned to GRCh38 or mm10,
589 respectively. Cutoffs for cell barcode calling were >3,000 ATAC fragments overlapping peaks for
590 human and >10,000 for mouse barcodes (based on empirical density). Doublet barcodes were
591 defined as containing more than 10% ATAC fragments aligning to both GRCh38 and mm10
592 reference genomes. The EGFP PDT count table was generated as described above by searching
593 PDT fastqs for the corresponding phage barcode (**Supplementary Table 4**) and deriving PDT-
594 associated cell barcodes via filtering using the entire list of called cell barcodes (human and
595 mouse).

596

597 After flow cytometry measurement of HEK293T-EGFP-GPI (EGFP⁺) and HEK293T cells (EGFP⁻
598), FCS files were exported using CytExpert Software (Beckman Coulter). Values for forward
599 scatter (FSC area) and EGFP fluorescence (FITC area) were derived from FCS files. Human
600 EGFP⁺ and EGFP⁻ cells were defined based on the distribution of EGFP PDT counts (for PHAGE-
601 ATAC) or EGFP fluorescence represented by FITC-area values (for flow cytometry) by setting a
602 gate at the minimum value in-between both populations.

603

604 **Analysis of PBMC PHAGE-ATAC experiment**

605 Sequencing data from two libraries of PBMCs were processed using CellRanger-ATAC count to
606 the GRChg38 reference genome using all default parameters, yielding 7,792 high-quality PBMCs
607 (no filtering was applied beyond the CellRanger-ATAC knee call). We downloaded processed
608 CITE-seq PBMC data (Stoeckius et al., 2017) from the Gene Expression Omnibus (GSE100866).
609 After removing spiked-in mouse cells, this published dataset was jointly analyzed with the 7,972
610 PBMCs profiled by PHAGE-ATAC. We performed data integration using canonical correlation

611 analysis (Butler et al., 2018), using the 2,000 most variable RNA genes as is the default in Seurat.
612 Next, we performed RNA imputation for the ATAC-seq data using Seurat v3 with the default
613 settings (Stuart et al., 2019). Reduced dimensions and cell clusters were inferred using this merged
614 object via the first 20 canonical correlation components with the default Louvain clustering in
615 Seurat v3. Centered log ratio (CLR) normalized PDTs were visualized in the reduced dimension
616 space and a per-tag, per-cluster mean was further computed to further access staining efficiency
617 between the modalities (**Figure 1N**).

618
619 Cell annotations were derived based on well-established marker genes for PBMCs (**Supp. Fig.**
620 **10A**), and the granulocyte population was corroborated by high overall fragments but low
621 proportion of fragments overlapping chromatin accessibility peaks. For protein-based clustering
622 and analyses, we identified T-cell clusters from the integrated embedding (using the
623 chromatin/RNA data) and then further stratified into subpopulations based on the abundance of
624 the CD4 and CD8 CLR PDT abundances (**Supp. Fig. 10B**). Differential gene activity scores
625 between these populations were then computed using the default functionality in Seurat/Signac
626 (Wilcoxon rank-sum test).

627
628 **Analysis of cell hashing PHAGE-ATAC experiment**
629 One channel of sequencing data from the hashed, combined CD8-enriched T cells was processed
630 using CellRanger-ATAC count via the GRCh38 reference genome using all default parameters,
631 yielding 8,366 high-quality PBMCs (no filtering was applied beyond the CellRanger-ATAC knee
632 call). As we suspected the presence of contaminating B-cells, we first characterized cell states
633 using latent semantic indexing (LSI)-based clustering and dimensionality reduction using Signac

634 and Seurat (Stuart et al., 2019). Specifically, all detected peaks were used as input into LSI. The
635 first 20 LSI components (except for the first component, which was found to be correlated with
636 the per-cell sequencing depth) were used to define cell clusters using the default Louvain clustering
637 algorithm in Seurat. Per-cluster chromatin accessibility tracks were computed using a per million
638 fragments abundance for each cluster, as previously implemented (Lareau et al., 2020). These
639 chromatin accessibility tracks were used to annotate cell clusters based on promoter accessibility
640 of known marker genes.

641
642 To assign hash identities to cell barcodes, we utilized the HTODemux function from Seurat
643 (Stoeckius et al., 2018) with the positive.quantile parameter set at 0.98. This yielded 703 doublets,
644 1,225 negatives, and 6,438 singlets based on the abundance and distribution of CD8 hashtag PDTs.

645
646 To verify PHAGE-ATAC hashtag-based assignments, we performed mitochondrial DNA
647 genotyping using mgatk (Lareau et al., 2020) and nuclear genotyping and donor assignment using
648 souporcell (Heaton et al., 2020) with “--min_alt 8 --min_ref 8 --no_umi True -k 4 --skip_remap
649 True --ignore True” options, which resulted in 92.9% accuracy (99.3% singlet accuracy, 74%
650 overlap in called doublets), confirming the concordance of our hashing design.

651
652 **Cloning of PANL, a synthetic high-complexity phage nanobody library**
653 To generate randomized library inserts, three separate primer mixes (for long CDR3, medium
654 CDR3 and short CDR3 inserts) were used for PCR-mediated assembly. For short CDR3-inserts,
655 the primer mix contained 0.5 μ l each of polyacrylamide gel electrophoresis-purified EF42, EF43,
656 EF64, EF44, EF65, EF45, EF46, EF47, EF66 and EF48 (each 100 μ M) (EllaBiotech). For medium

657 CDR3-inserts, EF67 was used instead of EF66. For long CDR3-inserts, EF68 was used instead of
658 EF66. Primer mixes were diluted 1:25 and 1 μ l of each mix was used for overlap-extension PCR
659 using Phusion (NEB). Four 50 μ l reactions for each mix were performed using cycling conditions
660 98°C 1min; 20cycles 98°C 15sec, 60°C 30sec, 72° 30sec; final extension 72°C 5min. PCR
661 reactions of the same mix were pooled and purified by addition of 280 μ l AMPure XP beads
662 (Beckman Coulter). Beads were washed twice with 800 μ l 80% ethanol and assembled inserts were
663 eluted in 100 μ l water. Concentrations of each insert (long, medium, short) were determined and
664 pooled in a 1:2:1 molar ratio. Five identical 50 μ l PCR reactions with pooled inserts and primers
665 EF40 and EF41 were performed using Phusion (NEB), cycling conditions were 98°C 1min;
666 30cycles 98°C 15sec, 62°C 30sec, 72° 30sec; final extension 72°C 5min. Amplified library insert
667 was pooled and purified by adding 350 μ l AMPure XP beads (Beckman Coulter). Beads were
668 washed twice with 1ml 80% ethanol and library insert was eluted in 60 μ l water. Five identical
669 60 μ l restriction digest reactions for digest of 7.5 μ g library vector pDXinit-PAC with 2.5 μ l SapI
670 were performed. Library insert (4.8 μ g) was digested in a 30 μ l reaction using 2.5 μ l SapI. Digests
671 were incubated for 4h at 37°C and loaded on 1% agarose gels. Bands corresponding to digested
672 library vector and insert were cut and products were extracted using GeneJet Gel Extraction Kit
673 (Thermo Scientific) and eluted in 40 μ l water. Five identical 100 μ l ligation reactions were
674 performed, each containing 1.25 μ g digested pDXinit-PAC, 450ng digested insert and 0.5 μ l T4
675 ligase (NEB). Ligations were incubated for 16h at 16°C, heat-inactivated for 20min at 65°C and
676 cooled to room temperature. 100 μ l AMPure XP beads were added to each ligation reaction, beads
677 were washed twice using 300 μ l 80% ethanol and ligation products were eluted in 15 μ l water and
678 pooled. Five electroporations in 2mm cuvettes (BioRad) were performed, each using 90 μ l electro-
679 competent SS320 *E. coli* (Lucigen) and 12 μ l ligation product. Pulsing was performed on a

680 GenePulserXcell instrument (BioRad) with parameters 2.5kV, 200Ohm, 25 μ F. After
681 electroporation, bacterial suspensions were added to 120ml pre-warmed SOC and incubated for
682 30min, 37°C, 225rpm. An aliquot of library-carrying bacteria was saved at this point and used to
683 prepare a dilution series. Each dilution was plated on LB-Ampicillin plates. After overnight
684 incubation at 37°C, colonies were counted, transformation efficiency was determined and library
685 complexity was estimated. The remaining 120ml of library-containing culture were added to
686 1.125L 2YT/2%/A/T and incubated overnight at 37°C, 240rpm. The library-containing culture was
687 harvested, glycerol stocks were prepared and library aliquots were stored.

688

689 **Analysis of picked PANL clones using PCR and Sanger sequencing**

690 Library-containing bacteria were plated on LB-Ampicillin, incubated overnight, and colonies were
691 picked and inoculated in 8ml LB-Ampicillin. Cultures were incubated for at least 8h at 37°C,
692 240rpm. Bacteria were harvested and plasmids isolated using GeneJet Plasmid Miniprep kit
693 (Thermo Scientific). PCR was performed to evaluate clone inserts. 10 μ l PCR reactions were set
694 up that contained 10ng of isolated plasmid, 0.5 μ l each of primers EF52 and EF53, and 4.5 μ l 2x
695 OneTaq Quick Load Master Mix (NEB). Cycling conditions were 94°C 4min; 28cycles 94°C
696 15sec, 62°C 15sec, 68°C 30sec; final extension 68C 5min. PCR reactions were analyzed on 2%
697 agarose gels. Selected clones were analyzed by Sanger Sequencing using primer EF17. Observed
698 amino acid frequencies at hypervariable positions were assessed by analyzing Sanger sequences
699 of 25 picked clones.

700

701 **Phage nanobody library production**

702 A PANL aliquot corresponding to 3×10^{10} bacterial cells (around 5x coverage of the library) was
703 transferred to 200ml 2YT/2%/A/T and cultures were grown until OD600=0.5 was reached (~2h).
704 Cultures were infected with 8ml M13K07 helper (NEB) for 60min at 37°C. Cultures were
705 harvested, supernatants discarded and bacterial pellets were resuspended in 1L 2YT/A/K. Cultures
706 were incubated overnight at 37°C, 250rpm for production of the input library of phage nanobody
707 particles. Bacterial cultures were harvested, supernatants collected and phages were precipitated
708 using PEG/NaCl as described earlier. Final phage pellets were resuspended in a total of 20ml PBS
709 and stored. Phage titers were determined by infecting a log-phase culture of SS320 with a dilution
710 series of the produced phage library and plating bacteria on LB-Ampicillin. Colonies were counted
711 and titers were calculated. Produced phage libraries were characterized by titers $> 4 \times 10^{11}$ pfu/ml.

712

713 **Phage display selection**

714 HEK293T cells were transfected either with pCAG or pCAG-EGFP-GPI as described above. Cells
715 were harvested, 10^7 pCAG-transfected cells were resuspended in 1ml PBS containing 2% BSA
716 (PBS-BSA), and 8ml PANL library (1.6×10^{12} pfu) in PBS-BSA were added for counter-selection.
717 Samples were incubated for 1h on a rotating wheel at 4°C and then centrifuged at 350g, 5min, 4°C.
718 Supernatants containing phages were added to 10^7 pCAG-EGFP-GPI expressing cells for positive
719 selection. After 1h on a rotating wheel at 4°C, samples were centrifuged (350g, 5min, 4°C) and
720 washed 6 times with PBS-BSA to remove unbound phages. Cells were washed once in PBS,
721 centrifuged and cell pellets were resuspended in 500μl Trypsin solution (1mg/ml Trypsin (Sigma
722 Aldrich) in PBS) to elute bound phages. Cells were incubated for 30min on a rotating wheel at
723 room temperature and digests were stopped by addition of AEBSF protease inhibitor (Sigma
724 Aldrich) to a final concentration of 0.5mg/ml. Samples were centrifuged (400g, 4min at room

725 temperature) and the supernatant containing eluted phages was used to infect 10ml of log-phase
726 SS320 (OD₆₀₀=0.4). After infection for 40min at 37°C, cultures were added to 90ml 2YT/2%/A/T
727 and incubated overnight at 37°C, 250rpm. Cultures containing output libraries were aliquoted and
728 glycerol stocks were prepared. Output library phage particles were prepared as described earlier
729 for PANL and used in subsequent selection rounds using the same protocol described here.

730

731 **Acknowledgements**

732 We thank L. Gaffney for assistance with figure illustrations and preparation, C. de Boer and other
733 members of the Regev laboratory for helpful discussion. We acknowledge support from the Broad
734 Institute Flow Cytometry Core facility. This research was supported by NHGRI grants 5RM1
735 HG006193 (Center for Cell Circuits), a gift from the Food Allergy Science Initiative, a gift from
736 the Manton Foundation, and HHMI (to AR). E.F. is supported by an EMBO Long-Term
737 fellowship. C.A.L. is supported by a Stanford Science Fellowship. A.R. was a Howard Hughes
738 Medical Institute Investigator (until July 31, 2020).

739

740 **Author Contributions**

741 E.F. conceived and designed the project with guidance from A.R. E.F. designed and performed
742 experiments. E.F. developed the PHAGE-ATAC computational workflow with input from C.A.L.
743 E.F. developed the PHAGE-ATAC experimental protocol with input from L.S.L. E.F. and C.A.L
744 analyzed the data. G.E. contributed to data analysis. A.R. provided project oversight and acquired
745 funding. E.F. and A.R. wrote the manuscript with input from all authors.

746

747 **Corresponding authors**

748 Correspondence to E.F. (efiskin@broadinstitute.org) and A.R. (aregev@broadinstitute.org)

749

750 **Competing Interests statement**

751 A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas
752 Therapeutics and until August 31, 2020 was an SAB member of Syros Pharmaceuticals, Neogene
753 Therapeutics, Asimov and ThermoFisher Scientific. From August 1, 2020, A.R. is an employee of
754 Genentech. The Broad Institute has filed for a patent related to PHAGE-ATAC where E.F. and
755 A.R. are named inventors.

756

757 **References**

758 Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell
759 transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 36, 411-
760 420.

761 Gebauer, M., and Skerra, A. (2009). Engineered protein scaffolds as next-generation antibody
762 therapeutics. *Curr Opin Chem Biol* 13, 245-255.

763 Geertsma, E.R., and Dutzler, R. (2011). A versatile and efficient high-throughput cloning tool for
764 structural biology. *Biochemistry* 50, 3272-3278.

765 Gehring, J., Hwee Park, J., Chen, S., Thomson, M., and Pachter, L. (2020). Highly multiplexed
766 single-cell RNA-seq by DNA oligonucleotide tagging of cellular proteins. *Nat Biotechnol* 38, 35-
767 38.

768 Heaton, H., Talman, A.M., Knights, A., Imaz, M., Gaffney, D.J., Durbin, R., Hemberg, M., and
769 Lawniczak, M.K.N. (2020). Souporcell: robust clustering of single-cell RNA-seq data by genotype
770 without reference genotypes. *Nat Methods* 17, 615-620.

771 Hoogenboom, H.R. (2005). Selecting and screening recombinant antibody libraries. *Nat*
772 *Biotechnol* *23*, 1105-1116.

773 Ingram, J.R., Schmidt, F.I., and Ploegh, H.L. (2018). Exploiting Nanobodies' Singular Traits.
774 *Annu Rev Immunol* *36*, 695-715.

775 Katzenelenbogen, Y., Sheban, F., Yalin, A., Yofe, I., Svetlichnyy, D., Jaitin, D.A., Bornstein, C.,
776 Moshe, A., Keren-Shaul, H., Cohen, M., *et al.* (2020). Coupled scRNA-Seq and Intracellular
777 Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer. *Cell* *182*, 872-885
778 e819.

779 Klein, A.M., Mazutis, L., Akartuna, I., Tallapragada, N., Veres, A., Li, V., Peshkin, L., Weitz,
780 D.A., and Kirschner, M.W. (2015). Droplet barcoding for single-cell transcriptomics applied to
781 embryonic stem cells. *Cell* *161*, 1187-1201.

782 Kubala, M.H., Kovtun, O., Alexandrov, K., and Collins, B.M. (2010). Structural and
783 thermodynamic analysis of the GFP:GFP-nanobody complex. *Protein Sci* *19*, 2389-2401.

784 Lareau, C.A., Duarte, F.M., Chew, J.G., Kartha, V.K., Burkett, Z.D., Kohlway, A.S., Pokholok,
785 D., Aryee, M.J., Steemers, F.J., Lebofsky, R., *et al.* (2019). Droplet-based combinatorial indexing
786 for massive-scale single-cell chromatin accessibility. *Nat Biotechnol* *37*, 916-924.

787 Lareau, C.A., Ludwig, L.S., Muus, C., Gohil, S.H., Zhao, T., Chiang, Z., Pelka, K., Verboon, J.M.,
788 Luo, W., Christian, E., *et al.* (2020). Massively parallel single-cell mitochondrial DNA genotyping
789 and chromatin profiling. *Nat Biotechnol*.

790 Ludwig, L.S., Lareau, C.A., Ulirsch, J.C., Christian, E., Muus, C., Li, L.H., Pelka, K., Ge, W.,
791 Oren, Y., Brack, A., *et al.* (2019). Lineage Tracing in Humans Enabled by Mitochondrial
792 Mutations and Single-Cell Genomics. *Cell* *176*, 1325-1339 e1322.

793 Ma, A., McDermaid, A., Xu, J., Chang, Y., and Ma, Q. (2020). Integrative Methods and Practical
794 Challenges for Single-Cell Multi-omics. *Trends Biotechnol* *38*, 1007-1022.

795 Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas,
796 A.R., Kamitaki, N., Martersteck, E.M., *et al.* (2015). Highly Parallel Genome-wide Expression
797 Profiling of Individual Cells Using Nanoliter Droplets. *Cell* *161*, 1202-1214.

798 McGinnis, C.S., Patterson, D.M., Winkler, J., Conrad, D.N., Hein, M.Y., Srivastava, V., Hu, J.L.,
799 Murrow, L.M., Weissman, J.S., Werb, Z., *et al.* (2019). MULTI-seq: sample multiplexing for
800 single-cell RNA sequencing using lipid-tagged indices. *Nat Methods* *16*, 619-626.

801 McMahon, C., Baier, A.S., Pascolutti, R., Wegrecki, M., Zheng, S., Ong, J.X., Erlandson, S.C.,
802 Hilger, D., Rasmussen, S.G.F., Ring, A.M., *et al.* (2018). Yeast surface display platform for rapid
803 discovery of conformationally selective nanobodies. *Nat Struct Mol Biol* *25*, 289-296.

804 Miersch, S., and Sidhu, S.S. (2012). Synthetic antibodies: concepts, potential and practical
805 considerations. *Methods* *57*, 486-498.

806 Mimitou, E.P., Cheng, A., Montalbano, A., Hao, S., Stoeckius, M., Legut, M., Roush, T., Herrera,
807 A., Papalex, E., Ouyang, Z., *et al.* (2019). Multiplexed detection of proteins, transcriptomes,
808 clonotypes and CRISPR perturbations in single cells. *Nat Methods* *16*, 409-412.

809 Paul, F., Arkin, Y., Giladi, A., Jaitin, D.A., Kenigsberg, E., Keren-Shaul, H., Winter, D., Lara-
810 Astiaso, D., Gury, M., Weiner, A., *et al.* (2015). Transcriptional Heterogeneity and Lineage
811 Commitment in Myeloid Progenitors. *Cell* *163*, 1663-1677.

812 Peterson, V.M., Zhang, K.X., Kumar, N., Wong, J., Li, L., Wilson, D.C., Moore, R., McClanahan,
813 T.K., Sadekova, S., and Klappnenbach, J.A. (2017). Multiplexed quantification of proteins and
814 transcripts in single cells. *Nat Biotechnol* *35*, 936-939.

815 Pollock, S.B., Hu, A., Mou, Y., Martinko, A.J., Julien, O., Hornsby, M., Ploder, L., Adams, J.J.,
816 Geng, H., Muschen, M., *et al.* (2018). Highly multiplexed and quantitative cell-surface protein
817 profiling using genetically barcoded antibodies. *Proc Natl Acad Sci U S A* *115*, 2836-2841.
818 Roobrouck, A., Stortelers, C., Vanlandschoot, P., Staelens, S., Conde, M., Soares, H., and Schols,
819 D. (2016). Bispecific Nanobodies. US 2016/0251440 A1.
820 Rothbauer, U., Zolghadr, K., Tillib, S., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N.,
821 Conrath, K., Muyldermans, S., Cardoso, M.C., *et al.* (2006). Targeting and tracing antigens in live
822 cells with fluorescent nanobodies. *Nat Methods* *3*, 887-889.
823 Satpathy, A.T., Granja, J.M., Yost, K.E., Qi, Y., Meschi, F., McDermott, G.P., Olsen, B.N.,
824 Mumbach, M.R., Pierce, S.E., Corces, M.R., *et al.* (2019). Massively parallel single-cell chromatin
825 landscapes of human immune cell development and intratumoral T cell exhaustion. *Nat Biotechnol*
826 *37*, 925-936.
827 Smith, G.P. (1985). Filamentous fusion phage: novel expression vectors that display cloned
828 antigens on the virion surface. *Science* *228*, 1315-1317.
829 Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P.K.,
830 Swerdlow, H., Satija, R., and Smibert, P. (2017). Simultaneous epitope and transcriptome
831 measurement in single cells. *Nat Methods* *14*, 865-868.
832 Stoeckius, M., Zheng, S., Houck-Loomis, B., Hao, S., Yeung, B.Z., Mauck, W.M., 3rd, Smibert,
833 P., and Satija, R. (2018). Cell Hashing with barcoded antibodies enables multiplexing and doublet
834 detection for single cell genomics. *Genome Biol* *19*, 224.
835 Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y.,
836 Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data.
837 *Cell* *177*, 1888-1902 e1821.

838 Tavernier, J., Cauwels, A., Kley, N., and Gerlo, S. (2017). CD8 Binding Agents. WO 2017/134306

839 Al.

840

Figure 1






Figure 2



Supp. Figure 1


A Nanobody-displaying phages (PHAGE-ATAC)

Genetically encoded barcode




B Antibody–oligonucleotide conjugates (CITE-seq, REAP-seq)


Chemically conjugated barcode




Supp. Figure 2




Supp. Figure 3




Supp. Figure 4




Supp. Figure 5




Supp. Figure 6





Supp. Figure 7



Supp. Figure 8




Supp. Figure 9




Supp. Figure 10


A




B




C




D



E




Supp. Figure 11




Supp. Figure 12


A



B




C



D

| Clone | CDR1 | CDR2 | CDR3 | CDR3 length |
|-------|---------------|---------------------------|-------------------------------------|-------------|
| 4 | N I F T Y G Y | L V A T I D Y G G T N T Y | V G Y G G G S L - - - - - Y T | Short |
| 7 | T I F W D E H | F V A T I D D G G S T Y | V S F S R H T D Y S D R - - - L N | Medium |
| 8 | S I F Q P V D | L V A S I G W G G S T N | V L G Y D S N T R D T G Y Y K W H G | Long |
| 11 | T I F V W L Y | L V A T I T G G G S T N | V G N T P D F S D E G Q - - - F W | Medium |
| 12 | T I S Y K G D | F V A S I N R G G I T N | V G Y S Y Y Q A S S K G - - - L R | Medium |
| 14 | N I F G N T D | L V A G I G A G G I T N | V D Y V S Q Q Y Y S S Y T H A V F T | Long |
| 16 | Y I S Y Y N S | F V A T I D T G S I T Y | V V V S T S I H D G K D K D F Q L Q | Long |
| 18 | Y I S V W Q G | L V A A I S Y G G T T Y | A I T I L A W L - - - - - F Y | Short |
| 19 | T I F Y G S Y | F V A A I A E G G S T Y | V V I E W E G Y G P R L Y L G A F L | Long |
| 20 | S I S P W Y A | L V A G I N G G G N T Y | A Q G L P P E S S V A Y - - - L A | Medium |
| 22 | S I S A W D V | F V A T I T R G T N T Y | A Y W T D Y Q Y - - - - - Y G | Short |
| 24 | Y I S D R G T | F V A A I G A G S I T Y | V P E L Y Y G G A W N F Y S T P F V | Long |
| * | * | * | * | |

Supp. Figure 13



Supp. Figure 14

PHAGE-ATAC

| | |
|--------------------------------------------|------------------|
| Ordering Nb sequence (IDT, ~370 bp) | ~ 22.2 \$ |
| Phagemid cloning | ~ 25 \$ |
| Phage production purification (10 rxns) | ~ 25 \$ |
| Barcoded phage nanobodies 10 rxns | ~ 72.2 \$ |
| Cost per rxn | ~ 7.22 \$ |

One time cost

PHAGE-ATAC

| | |
|---------------------------------------------|------------------|
| Ordering Nb sequence (IDT, ~370 bp) | ~ 22.2 \$ |
| Phagemid cloning | ~ 25 \$ |
| Phage production purification (100 rxns) | ~ 250 \$ |
| Barcoded phage nanobodies 100 rxns | ~ 297.2 \$ |
| Cost per rxn | ~ 2.97 \$ |

One time cost